Overview

To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine an effective and safe dose of ACE-011 for the treatment of chemotherapy induced anemia (CIA) in participants with metastatic non-small cell lung cancer who are being treated with first-line platinum based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation